Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2009.

"We have now completed the clinical development program for Acetavance(TM), our proprietary formulation of intravenous acetaminophen for the treatment of acute pain and fever in adults and children, and plan to submit a New Drug Application for Acetavance in the second quarter of 2009," stated Ted Schroeder, President and CEO of Cadence Pharmaceuticals. "We also achieved another important corporate objective earlier this year by raising gross proceeds of $86.6 million through a private placement of common stock and warrants. We believe this additional capital strengthens our balance sheet and will enable us to prepare for the launch of Acetavance, if approved by the FDA."

In March 2009, Cadence announced that its Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections did not meet its primary endpoint and that, as a result, the company made the strategic decision to discontinue further development of this product candidate. In order to reduce operating costs following this decision, Cadence implemented a restructuring plan, including a workforce reduction.

First Quarter 2009 Financial Results

For the first quarter ended March 31, 2009, Cadence reported a net loss of $10.4 million, or $0.24 per share, compared to a net loss of $13.7 million, or $0.42 per share, for the same period in 2008. The per share amount for the first quarter of 2009 includes the effect of the issuance of 12,039,794 shares
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , ... September 04, 2015 , ... Canadian astronomer David ... observation logs he has maintained for nearly 60 years to the Linda Hall ... 9 that collided with Jupiter in 1994 — an episode that produced the first ...
(Date:9/4/2015)... 2015 Research and ... the "Biopreservation Market by Product, Biospecimen, Application ... report to their offering. The ... 3,731.03 Million by 2020 from USD 2,150.48 Million ... between 2015 and 2020. Biopreservation ensures ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... desktop 3D bioprinter, the BioBot 1, at the 2015 TERMIS World Congress in ... leading tissue and biomedical engineering institutions around the world. The printer is revolutionary ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... safety and pharmacovigilance services and software tools to pharmaceutical and life sciences organizations, ... Allergan Japan. PRIMO Mobile is a mobile data intake solution that enables field ...
Breaking Biology Technology:Renowned Astronomer David Levy To Donate Night Sky Observation Logs to the Linda Hall Library 2Renowned Astronomer David Levy To Donate Night Sky Observation Logs to the Linda Hall Library 3Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 2Global Biopreservation Market 2015-2020 - Product, Biospecimen, Application and End User Analysis of the $3.73 Billion Industry 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 2BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 4November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2
... Prepare for Zingo Launch ... Promoted To Senior Vice President, Marketing and Sales, and ... - Additional Manufacturing Capacity in China -, - Details to be Presented at Investor Briefing Today at ... Time -, ...
... TPPII may contribute to obesity by stimulating the formation of ... The enzyme, TPPII, has previously been linked to making people ... it may be even more deeply involved in causing obesity. ... of fat cells in worms and mammalian cells and that ...
... Ill. New sol-gel inks developed by researchers at ... to produce three-dimensional structures of metal oxides with nanoscale ... at the nanoscale opens a new avenue to functional ... gas sensors., The researchers describe the new inks in ...
Cached Biology Technology:Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7Sol-gel inks produce complex shapes with nanoscale features 2
(Date:9/2/2015)... , Sept. 2, 2015 About hand ... for enterprises, banks, government organizations, telecommunication and hospitals as ... Keys, identity badges, and numeric keypads are used to ... structure of palm and fingers of an individual, width ... geometry scanners with infrared light and reflectors can be ...
(Date:9/2/2015)... Sept. 2, 2015 Security of data ... enterprises, banks, government organizations, telecommunications, hospitals, as well ... were previously being used to prevent unauthorised access. ... authentication, wherein individuals could gain access to secure ... such as hardware devices and numeric codes. However, ...
(Date:9/2/2015)... , September 2, 2015 ... purpose implied in a system which uses identical ... signature, iris, vein, DNA and finger print. Increasing ... to develop such system which provides high level ... PIN, Patterns and tokens are vulnerable to attacks. ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... A human ancestor characterized by "robust" jaw and skull ... and more adaptive to its environment than previously thought, scientists ... hand, leg and foot fragments -- dated to 1.34 million ... the Olduvai Gorge World Heritage fossil site in Tanzania. The ...
... visually impaired navigate more safely and a system for ... concepts to win seed funding from Capital One Bank ... at the fifth annual Newark Innovation Acceleration Challenge. ... entrepreneurs, divided equally between teams of college students from ...
... with sharks, the world,s oldest ocean predators have long been ... white shark,s genetic code has fished up big surprises behind ... dinosaurs roamed. Cornell researchers have discovered that many of ... of different functions including metabolism match humans more ...
Cached Biology News:Discovery of partial skeleton suggests ruggedly built, tree-climbing human ancestor 2Inventions that improve lives are winners at the 2013 Newark Innovation Acceleration Challenge 2Inventions that improve lives are winners at the 2013 Newark Innovation Acceleration Challenge 3New genetic research finds shark, human proteins stunningly similar 2
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Biology Products: